A Single-arm Open Label Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 04 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.
- 04 Aug 2017 Status changed from active, no longer recruiting to recruiting.
- 27 Feb 2017 Status changed from recruiting to active, no longer recruiting.